JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
Read original at benzingaStocks · News reference
8-K filing — Amneal Pharmaceuticals, Inc. (AMRX)
Filed: 2026-07-31 AccNo: 0001140361-26-030491 Size: 168 KB Item 5.07: Submission of Matters to a Vote of Security Holders
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 31, 2026, 8:08 PM
- Checked
- Jul 31, 2026, 8:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Amneal Pharmaceuticals, Inc. (AMRX)
Filed: 2026-08-03 AccNo: 0001628280-26-051900 Size: 79 MB Item 1.01: Entry into a Material Definitive Agreement
Read original at edgarUBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
Read original at benzingaAmneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200
Read original at benzinga